USE OF LACTIC ACID BACTERIUM FOR THE TREATMENT OF PERITONITIS

Abstract: The present invention pertains to the use of lactic acid bacteria capable to adhere to the intestine's mucosa and essentially colonize it for the treatment of disorders associated with peritonitis. In particular, the present invention relates to the use of such lactic acid bacteria for the treatment of peritonitis caused by liver cirrhosis.

Description: USE OF LACTIC ACID BACTERIUM FOR THE TREATMENT OF PERITONITIS The present invention pertains to the use of lactic acid bacteria capable to adhere to the intestine's mucosa and essentially colonize it for the treatment of disorders associated with peritonitis. In particular, the present invention relates to the use of such lactic acid bacteria for the treatment of peritonitis' associated with liver cirrhosis. Peritonitis is an inflammation of the peritoneum, attributable to a severe local infection regularly resulting from gastrointestinal inflammation and infection, gastro-intestinal perforation and trauma, including surgery or peritoneal dialysis. To this end, pathogenic and potentially pathogenic microorganisms and occasionally cellular debris enter the peritoneum and elicit an immune response by the host, which may often not cope with the challenge of the pathogenic invasion. This hold true in particular for patients suffering from liver cirrhosis. Cirrhotic patients commonly have intestinal bacterial overgrowth and a decreased immune response, which seems to be at least in part due to an inferior opsonic activity in the ascitic fluid. Advanced cirrhosis is therefore quite often accompanied by a spontaneous bacterial peritonitis (SBP) usually involving gram-negative, enteric pathogens that are normally found in the intestine. Developing SBP in the ascitic fluid is therefore deemed to be caused by bacterial translocation of intestinal bacteria into the peritoneum. A major jeopardy of peritonitis is bacterial dissemination, i.e. the spread of the pathogens via the blood and lymph systems, resulting in the infection of diverse tissues and leading to a life threatening situation for the affected individual. Once bacteria have entered the peritoneal cavity, dissemination is quite rapid. Within 6 minutes of intraperitonal inoculation of bacteria in dogs, thoracic lymph has been found culture-positive, while within 12 minutes elevated bacterial levels in the bloodstream may be found. Although several advances in diagnosis and treatment of peritonitis were made still about one third of hospitalized patients with this infection eventually die from gastrointestinal bleeding, liver failure or the hepatorenal syndrom. At present the typical medical treatment for the prevention and/or treatment of peritonitis includes antibiotic therapy, especially prior to surgical procedures. This approach suffers, however, from the drawback ofdeveloping drug resistant bacteria known to cause peritonitis. Moreover, since peritonitis may be caused by both gram-positive and gram-negative microorganisms, the use of an antibiotic may not be sufficient in all cases. In addition, antibiotic treatment is non-specific, also exterminating many non-pathogenic microorganisms which commonly prevent bacterial diseases through bacterial antagonism, in particular in the gastrointestinal tract. Therefore, in applying broad spectrum antibiotics for prolonged periods the growth of most of the bacteria thriving in the intestinal tract is suppressed with the result of antibiotic resistant strains of pathogenic micro-organisms freely propagating. In consequence, antibiotics may occasionally foster peritonitis, rather than prevent it. Another approach for the treatment of peritonitis is disclosed in WO 97/00081. This document suggests the use of antagonists to CD 14, a surface antigen known to interact with lipopolysaccharides of bacterial origin. Bacterially derived lipopolysaccharides are known to be capable to stimulate the immune system by binding to cell surface receptors of cells of the immune system which in turn start to produce and secrete cytokines and other mediators, that stimulate the immune system. However, said cytokines or mediators, respectively, have also been found to be able to support bacterial growth and invasiveness. The gist of the treatment proposed therefore lies in an interruption of the early immune response during which the cytokines/mediators are produced. It is thought that in essentially preventing the production of the cytokines by blocking activation via CD 14 the growth of the bacteria is not promoted as well. Yet this method suffers from the drawback that the immune response is essentially impeded as well, so that the host's own defense mechanism is deteriorated. Consequently, there is a need for an effective method for the prevention and/or treatment of local infections, such as those associated with peritonitis. An object of the present invention is therefore to provide such a means. During the extensive experimentation leading to the present invention the inventors have investigated the theory whether lactic acid bacteria in the gut of an individual may have a positive influence on the cells of the immune system in the peritoneum, especially on the cells of the immune system adjacent to the intestine. It has been found that the administration of particular lactic acid bacteria obviously reduce the number of bacterial counts in the ascites and the peritoneum, respectively, of animals suffering from peritonitis, showing that lactic acid bacteria bacteria, in particular probiotic lactic acid bacteria bacteria are able to efficiently decrease intestinal bacterial overgrowth and translocation of pathogens. The above problem has therefore been solved by providing the use of lactic acid bacteria, that are capable to adhere to the intestine's mucosa and essentially colonize it, for the preparation of an ingestable carrier for preventing and/or treating disorders associated with peritonitis. The peritonitis may be a spontaneous bacterial peritonitis (SBP) such as is caused by the sudden appearance of potential pathogens in the peritoneum, which often concurs with a deficiency of liver function, such as during a cirrhotic state thereof. Moreover the peritonitis may well be virally induced or a peritonitis following dialysis or surgery. According to a preferred embodiment the lactic acid bacterium is a probiotic lactic acid bacterium, preferably from the genus Lactobacillus or Bifidobacterium, and is more preferably Lactobacillus johnsonii CNCM 1-1225, Lactobacillus paracasei CNCM 1-2116 or Bifidobacterium CNCM 1-2168. According to the present invention the lactic acid bacterium to be used is incorporated in the carrier which may be a food or a pharmaceutical product, such as e.g. milk, yoghurt, curd, cheese, fermented milks, milk based fermented products, ice-creams, fermented cereal based products, milk based powders, infant formulae and in forms of tablets, liquid bacterial suspensions, dried oral supplements, wet oral supplement, dry tube feeding or wet tube feeding etc. The carrier may well include other compounds known to be beneficial to an impared situation of the gut, e.g. antioxidants, such as Vit C, Nit E, Selenium or Zinc. Depending on the respective treatment and/or the preventive therapy the person skilled in the art will choose the appropriate galenic form and/or supplements, assisting in improving the individual's health. Without being bound to any theory the activity of the micro-organism is believed to be mainly due to two factors: Probiotics are known to have a beneficial effect on the host's immune system. In the present case it seems as if the lactic acid bacteria are capable to stimulate the immune system in the peritoneum and in particular the non-specific immune defense, located around the individual's gut to combat microorganisms invading the peritoneum through the intestine's walls. This immune barrier is normally weakened in patients suffering from liver cirrhosis. On the other hand it is thought that the lactic acid bacteria colonizing the intestine's wall will physically prevent or at least reduce the number of potential pathogens invading the peritoneum via the gut. Through adhesion to the intestine the bacteria obviously establish a close contact with the intestinal mucosa masking receptors of the intestine's surface for pathogens. As will be appreciated, the activity of the micro-organisms is dose dependent with the effect that the more micro-organisms are incorporated by means of ingesting the food or pharmaceutical composition, respectively, the higher the protective and/or curing activity. Thus, the food or pharmaceutical composition to be used according to the present invention may contain the lactic acid bacterium in an amount from about 10 s cfu/g to about 10' 2 cfu/g carrier. For the purpose of the present invention the abbreviation „cfu" shall designate a „colony forming unit" that is defined as the number of bacterial cells as revealed by microbiological counts on agar plates. Since the micro-organisms used are not obnoxious to mankind and animals and have eventually been isolated from a natural surrounding, namely baby feces, a high amount thereof may be incorporated so that essentially a high proportion of the individuals intestine may be colonized by the micro-organisms. The invention will now be described by means of examples which are not construed to limit it to the embodiments. Example 1 Treatment of animals A total of 31 male Sprague-Dawley rats were included in the study with 19 thereof being made cirrhotic by weekly intragastric administration by gavage of carbon tetrachloride and water with phenobarbital (1.5mmol/l) ad libitum. The diet has been standard B&K (Barcelona, Spain) and was available for the rats ad libitum. The 12 rats from control group received standard diet (supra) and water with phenobarbital during all the study, while the other rats (19) of the test group received the standard diet inclusive the lactic acid bacterium CNCM 1-1225 (Lactobacillus johnsonii, Lai) in an amount of about 10 10 cfu/day or water. All control rats were killed 18 weeks after they began to drink water with phenobarbital. From 12 control rats, 6 received treatment A (water) and 6 treatment B (water plus lactobacillus). The treatment was administered by gavage. Laparotomy was performed under anesthesia after 10 days of respective treatment or no treatment and samples of cecal feces, ileal feces, ileum wall, mesenteric lymph nodes and ascitic and pleural fluid were collected for the microbiological study. Blood was collected from cava vein to determine endotoxemia. In addition, samples of ileal wall, cecal wall, spleen and liver were collected for histological study, and portal pressure was assessed both by portal vein puncture and the ratio spleen weight/rat weight. With the test group, when rats developed ascites (approximately after 20 weeks of the beginning of the induction oi cirrhosis), a paracentesis under anesthesia was performed to verify the presence of ascites, and they were distributed by randomization into two groups: one group (n=8) received treatment A (water) and another group (n=l 1) received treatment B (plus lactic acid bacterium). Treatment was administered by gavage. The procedures at the end of the study (after 10 days of treatment) were the same than in control rats. A study of intestinal permeability by the determination of lactulose and mannitol in urine was performed to all the control and cirrhotic rats during the 24 hours previous to the beginning of treatment and at the end of treatment. Moreover, the study of intestinal permeability was performed to all the control and cirrhotic rats every 4 weeks through the period of induction of cirrhosis or control. Example 2 Presence of ascites, bacterial translocation and bacterial peritonitis At the moment of laparotomy, 7/8 cirrhotic rats treated with water (treatment A) and 7/11 cirrhotic rats with treatment B had detectable ascitic fluid. Cultures of mesenteric lymph nodes were negative in all 22 control rats. Cultures of mesenteric lymph nodes, ascitic fluid and pleural fluid were also negative in all cirrhotic rats receiving treatment B. Considering cirrhotic rats receiving water, 5/8 rats showed bacterial translocation (positive cultures) to mesenteric lymph nodes or ascitic or pleural fluid (p<0.01 with respect to groups receiving treatment A and B): 2 to pleural fluid, 2 to mesenteric lymph nodes , and 1 to pleural and ascitic fluid and to mesenteric lymph nodes. Bacteria isolated were: 2 Escherichia coli, 2 E. coli + enterococcus, and 1 E. coli + streptococcus. The results are summarized in table I below: Table I From the above results it becomes obvious that bacterial translocation significantly decreased in cirrhotic rats receiving L. johnsonii CNCM 1225 as compared to cirrhotic rats receiving water. Example 3 Microbiological intestinal study In this study various microorganisms were tested for in the control and the cirrhotic rats treated as indicated in example 1 and 2 above. *p<0.01, **p<0.001 and ***p<0.03 with respect to cirrhotic rats treated with water (Mann- Whitney test). X #p<0.05 and ##p<0.01 with respect to cirrhotic rats treated with water. nd = not determined The above data also confirm the impaired intestinal microbial balance, i.e. intestinal bacterial overgrowth of potentially pathogenic bacteria in cirrhotic rats as compared to control rats. Treatment B decreased bacterial counts of enterobacteria and enterococcus and increased lactobacillus when compared to rats treated with water. Therefore, treatment B may correct the bacterial overgrowth of potentially pathogenic bacteria in cirrhotic rats. TBAITE BE BUDAPEST SUR LA RECONNAISSANCE INTERNATIONALE DU DEPOT DES HICRO-ORGANISHEΞ AUX FINS SE λ PROCEDURE EN HATIERE OS BREVETS FQRHULE INTERNATIONALE TDESTIMATAIRE 5 RECEPISSE EN CAS DE DEPOT INITIAL, I i delivrέ en vertu de la regie 7.1 par fessieurs Λ ARCHAMBAULT et WAVRE 1*AUTORITE OB DEPOT INTERNATIONALE • JESTEC S.A. identifies au bas de cette page Service des Brevets Formule BP/4 (page unique) TRAITE DE BUDAPEST SOS LA RECONNAISSANCE INTERNATIONAL * -" DU DEPOT DES MICROORGANISMES AUX PISS DE LA PROCEDURE EH MATURE DK BREVETS FORMULE 1NTERHAT10HALE ΓDESTINATAIRE I RECEFISSB EH CAS DE DEPOT INITIAL, dellvr€ en vertu de la rδgle 7.1 pae 1 ' AUTORITE DE DEPOT INTERNATIONALE identifi€e au baa da cette page SOCIETE DES PRODUITS NESTLE S.A. Patents department Avenue Nβsflέ 55 Ch SOO Vevey I NOM ET ADRESSE I 1 DU DEPOSANT ' autor te e ep t nternational-! a eta acquis. Formule BP/ 4 (page unique ) TRAITE DE BUDAPEST SUR LA RECONNAISSANCE IHTERHATIONALE DU DEPOT DES MICRO-ORGANISHES AUX PISS DE LA PROCEDURE EH ATIERE DE BREVETS FORMULE INTERNATIONALE |~D DEEST1NATA1RE I RECEPISSE EN CAS DE DEPOT INITIAL, dάlivrά en vertu de la regie 7.1 par 1'AUTORITE DE DEPOT IHTERHATIONALE identifiee au bas de cette page SOCIETE DES PRODUITS NESTLE S.A. Patents department Avenue Nestlέ 55 CH-l800 Vevey I NOM ET ADRESSE I 1 DU DEPOSANT ' IDENTIFICATION DU MICRO-ORCANISME Reference "identif cation donnέe par lc Numέro d'ordre attribuβ par DEPOSANT : 1 'AUTORITE DE DEPOT INTERNATIONALE NCC 251 1 - 2168 II. DESCRIPTION SCIENTIFIQUE ET/OU DESIGNATION TAXONOMIQUE PROPOSEE Le micro-organisme identifie sous chiffre I έtait accompagne d'une description scient fique d'une designation ta-cσnomique propoaέe (Cocher ce qui con.iθnt) III. RECEPTION ET ACCEPTATION La presente autorite de depot Internationale accepte le micro-organisme identifie sous chiffre I, qu'elle a recu le 15 MARS 1999 (date du depot initial) 1 IV. RECEPTION D'UNE REQUETE EN CONVERSION La presente autorite de d.epόt international-! a regu le micro-organisme identifie sous chiffre I le (data du dδpβt initial) et a recu une requete en conversion du depot initial en depot αonforne au Traite de Budapest le ' (date de reception de la requete en conversion) AUTORITE DE DEPOT INTERNATIONALE Nora Signature ( s ) de la (des) personne ( s ) CNCM competente ( s) pour reprisenter l'aυtoritέ Collection Nationale de depot Internationale α de l' (des ) de Cultures de Microorgaπlsmes employe es * ) " autorise(s) ' Adre3se INSTITUT PASTEUR 28, Rue du Docteur Roux F-75724 PARIS CEDEX 15 Date : Parts, le 10 aoQt 1 En cas d'applicatlon de la r&gle 6.4-d), cette date eat la date a laquelle le stacut d'autorite de depot Internationale a ete acquis. Formule BP/4 (page unique)

Claims: Claims 1. Use of a lactic acid bacterium capable to adhere to the intestine's mucosa and essentially colonize it for the preparation of an ingestable carrier for preventing and/or treating disorders associated with peritonitis. 2. The use according to claim 1, wherein the lactic acid bacterium is a probiotic bacterium. 3. The use according to any of the preceding claims, wherein the bacterium is selected from the group consisting of Lactobacillus or Bifidobacterium. "4. The use according to claim 3 wherein the bacterium is Lactobacillus johnsonii CNCM 1-1225, Lactobacillus paracasei CNCM 1-2116 or Bifidobacterium CNCM 1-2168. 5. The use according to any of the preceding claims wherein the peritonitis is spontaneous bacterial peritonitis (SBP), virally induced peritonitis or dialysis induced peritonitis (DIP). 6. The use according to any of the preceding claims wherein the peritonitis is associated with liver cirrhosis. 7. The use according to any of the preceding claims wherein the lactic acid bacterium is contained in the carrier in an amount from about 10 5 cfu/g to about 10 12 cfu/g carrier. 8. The use of a lactic acid bacterium according to claim 7, wherein the carrier containing the lactic acid bacterium is a food or pharmaceutical composition. The use according to claim 7, wherein the carrier is a food composition selected from milk, yoghurt, curd, cheese, fermented milks, milk based fermented products, icecreams, fermented cereal based products, milk based powders, infant formulae, tablets, liquid bacterial suspensions, dried oral supplement, wet oral supplement, dry tube feeding or wet tube feeding.

Inventors: GUARNER CARLOS, SCHIFFRIN EDUARDO, SORIANO GERMAN, GUARNER, CARLOS, SCHIFFRIN, EDUARDO, SORIANO, GERMAN
Applicants: GUARNER CARLOS, NESTLE SA, SCHIFFRIN EDUARDO, SORIANO GERMAN, GUARNER, CARLOS, SCHIFFRIN, EDUARDO, SOCIETE DES PRODUITS NESTLE S.A., SORIANO, GERMAN
Application year: 2001
Main classification: A61K35
IPC codes: A23C9, A23C19, A23G9, A23L1, A61K35, A61P1, A61P29, A61P31, A61P41